Pub Date : 2026-01-06DOI: 10.1016/j.ejso.2026.111392
Woong Ki Park , Namkee Oh , Gyu-Seong Choi , Bogeun Kim , Ki Jo Kim , Hee Jun Choi , Jinsoo Rhu , Jai Min Ryu
Purpose
Robot-assisted nipple-sparing mastectomy (RANSM) has gained acceptance in selected patients; however, identifying the safe dissection plane remains technically challenging due to the absence of tactile feedback. Artificial intelligence (AI)–guided navigation may provide intraoperative assistance, yet no externally validated model has been reported for this procedure.
Materials and methods
This retrospective study developed and validated an AI-guided navigation system to identify the safe dissection plane during RANSM. Surgical video data from 37 procedures performed between January 2021 and December 2024 at two tertiary centers in South Korea were analyzed (internal dataset, n = 29; external dataset, n = 8). The safe dissection plane was annotated as the visual boundary between subcutaneous fat and glandular tissue. An AI segmentation model was trained using 5-fold cross-validation on the internal dataset and tested on the independent external dataset. Model performance was assessed using the Dice Similarity Coefficient (DSC), with intersection over union (IOU), sensitivity, precision, and specificity as secondary metrics.
Results
A total of 1996 internal and 293 external frames were analyzed. The model achieved a mean DSC of 74.0 % (±1.5 %), IOU: 60.0 % (±1.8 %), sensitivity: 79.7 % (±1.9 %), and precision: 71.5 % (±1.6 %) in internal validation. On external validation, the DSC was 70.8 %, IOU: 55.9 %, sensitivity: 73.1 %, precision: 72.2 %, and specificity: 96.8 %.
Conclusion
This study is the first to develop and externally validate an AI-guided navigation system for RANSM. The model demonstrated consistent performance across two institutions, suggesting potential to enhance surgical precision and safety. Larger prospective studies are warranted to confirm clinical utility.
目的:机器人辅助乳头保留乳房切除术(RANSM)在特定患者中得到认可;然而,由于缺乏触觉反馈,确定安全的解剖平面在技术上仍然具有挑战性。人工智能(AI)引导的导航可以提供术中辅助,但没有外部验证的模型用于该手术的报道。材料和方法本回顾性研究开发并验证了人工智能引导的导航系统,以确定RANSM期间的安全解剖平面。分析了2021年1月至2024年12月在韩国两家三级中心进行的37次手术的手术视频数据(内部数据集,n = 29;外部数据集,n = 8)。安全剥离平面被标注为皮下脂肪和腺组织的视觉边界。在内部数据集上使用5倍交叉验证训练AI分割模型,并在独立的外部数据集上进行测试。使用Dice Similarity Coefficient (DSC)评估模型性能,并以intersection over union (IOU)、灵敏度、精度和特异性作为次要指标。结果共分析了96例内框和293例外框。模型内部验证的平均DSC为74.0%(±1.5%),IOU为60.0%(±1.8%),灵敏度为79.7%(±1.9%),精密度为71.5%(±1.6%)。经外部验证,DSC为70.8%,IOU为55.9%,灵敏度为73.1%,精密度为72.2%,特异性为96.8%。本研究是第一个开发和外部验证人工智能导航系统的RANSM。该模型在两家机构中表现出一致的性能,表明有可能提高手术精度和安全性。有必要进行更大规模的前瞻性研究以确认临床应用。
{"title":"Development and external validation of an AI-guided navigation system for the safe dissection plane in robot-assisted nipple sparing mastectomy","authors":"Woong Ki Park , Namkee Oh , Gyu-Seong Choi , Bogeun Kim , Ki Jo Kim , Hee Jun Choi , Jinsoo Rhu , Jai Min Ryu","doi":"10.1016/j.ejso.2026.111392","DOIUrl":"10.1016/j.ejso.2026.111392","url":null,"abstract":"<div><h3>Purpose</h3><div>Robot-assisted nipple-sparing mastectomy (RANSM) has gained acceptance in selected patients; however, identifying the safe dissection plane remains technically challenging due to the absence of tactile feedback. Artificial intelligence (AI)–guided navigation may provide intraoperative assistance, yet no externally validated model has been reported for this procedure.</div></div><div><h3>Materials and methods</h3><div>This retrospective study developed and validated an AI-guided navigation system to identify the safe dissection plane during RANSM. Surgical video data from 37 procedures performed between January 2021 and December 2024 at two tertiary centers in South Korea were analyzed (internal dataset, n = 29; external dataset, n = 8). The safe dissection plane was annotated as the visual boundary between subcutaneous fat and glandular tissue. An AI segmentation model was trained using 5-fold cross-validation on the internal dataset and tested on the independent external dataset. Model performance was assessed using the Dice Similarity Coefficient (DSC), with intersection over union (IOU), sensitivity, precision, and specificity as secondary metrics.</div></div><div><h3>Results</h3><div>A total of 1996 internal and 293 external frames were analyzed. The model achieved a mean DSC of 74.0 % (±1.5 %), IOU: 60.0 % (±1.8 %), sensitivity: 79.7 % (±1.9 %), and precision: 71.5 % (±1.6 %) in internal validation. On external validation, the DSC was 70.8 %, IOU: 55.9 %, sensitivity: 73.1 %, precision: 72.2 %, and specificity: 96.8 %.</div></div><div><h3>Conclusion</h3><div>This study is the first to develop and externally validate an AI-guided navigation system for RANSM. The model demonstrated consistent performance across two institutions, suggesting potential to enhance surgical precision and safety. Larger prospective studies are warranted to confirm clinical utility.</div></div>","PeriodicalId":11522,"journal":{"name":"Ejso","volume":"52 3","pages":"Article 111392"},"PeriodicalIF":2.9,"publicationDate":"2026-01-06","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145975080","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2026-01-05DOI: 10.1016/j.ejso.2026.111388
Luigi A. De Vitis , Faye R. Harris , Leah Grcevich , Ilaria Capasso , Stephen J. Murphy , James B. Smadbeck , Alexa F. McCune , Mohamed F. Ali , Giannoula Karagouga , Sarah H. Johnson , Dorsay Sadeghian , Gabriella Schivardi , Giuseppe Cucinella , Evelyn A. Reynolds , Grace M. Choong , Lin Yang , Alyssa M. Larish , Michael T. Barrett , Angela R. Emanuel , Janet L. Schaefer-Klein , Andrea Mariani
Introduction
Although circulating tumor DNA (ctDNA) has emerged as a promising prognostic tool in various malignancies, evidence in endometrial cancer at high risk of recurrence is limited. This study evaluated the association of pre- and post-surgical ctDNA with advanced-stage disease, disease-free and overall survival in endometrial cancer with high-risk features.
Material and methods
This prospective observational study was conducted at Mayo Clinic (7/2016-6/2021). Patients with endometrial cancer at preoperative biopsy, confirmed by final pathology, were included. Blood samples were collected before and 10 weeks after surgery. Tumor-specific junctions identified in pathology specimens and blood samples were used to detect ctDNA. Associations between pre- and post-surgical ctDNA and advanced-stage disease, recurrence, and death were evaluated using logistic regression [odds ratio (OR) and 95 % confidence interval] and Cox proportional hazards [hazard ratio (HR) and 95 % confidence interval].
Results
Thirty-six patients were included: 6 (16.7 %) intermediate risk, 1 (2.8 %) high-intermediate risk, 28 (77.8 %) high risk, and 1 (2.8 %) advanced metastatic. Detection of pre- or post-surgical ctDNA was not significantly associated with advanced disease (pre-surgical OR 5.69 [0.88–66.02]; post-surgical OR 5.86 [0.83–72.68]). Pre-surgical ctDNA did not significantly predict recurrence (HR 0.99 [0.30–3.23]) or death (HR 3.23 [0.40–25.91]). In contrast, post-surgical ctDNA was associated with increased risk of recurrence (HR 3.32 [1.05–10.51]) and death (HR 5.97 [1.11–36.08]).
Conclusion
Post-surgical ctDNA detection was associated with poor outcomes in patients with endometrial cancer. These findings support the potential of ctDNA as a biomarker to personalize surveillance and guide post-surgical treatment strategies.
{"title":"Prognostic value of perioperative circulating tumor DNA (ctDNA) in endometrial cancer with high-risk features: a prospective observational study","authors":"Luigi A. De Vitis , Faye R. Harris , Leah Grcevich , Ilaria Capasso , Stephen J. Murphy , James B. Smadbeck , Alexa F. McCune , Mohamed F. Ali , Giannoula Karagouga , Sarah H. Johnson , Dorsay Sadeghian , Gabriella Schivardi , Giuseppe Cucinella , Evelyn A. Reynolds , Grace M. Choong , Lin Yang , Alyssa M. Larish , Michael T. Barrett , Angela R. Emanuel , Janet L. Schaefer-Klein , Andrea Mariani","doi":"10.1016/j.ejso.2026.111388","DOIUrl":"10.1016/j.ejso.2026.111388","url":null,"abstract":"<div><h3>Introduction</h3><div>Although circulating tumor DNA (ctDNA) has emerged as a promising prognostic tool in various malignancies, evidence in endometrial cancer at high risk of recurrence is limited. This study evaluated the association of pre- and post-surgical ctDNA with advanced-stage disease, disease-free and overall survival in endometrial cancer with high-risk features.</div></div><div><h3>Material and methods</h3><div>This prospective observational study was conducted at Mayo Clinic (7/2016-6/2021). Patients with endometrial cancer at preoperative biopsy, confirmed by final pathology, were included. Blood samples were collected before and 10 weeks after surgery. Tumor-specific junctions identified in pathology specimens and blood samples were used to detect ctDNA. Associations between pre- and post-surgical ctDNA and advanced-stage disease, recurrence, and death were evaluated using logistic regression [odds ratio (OR) and 95 % confidence interval] and Cox proportional hazards [hazard ratio (HR) and 95 % confidence interval].</div></div><div><h3>Results</h3><div>Thirty-six patients were included: 6 (16.7 %) intermediate risk, 1 (2.8 %) high-intermediate risk, 28 (77.8 %) high risk, and 1 (2.8 %) advanced metastatic. Detection of pre- or post-surgical ctDNA was not significantly associated with advanced disease (pre-surgical OR 5.69 [0.88–66.02]; post-surgical OR 5.86 [0.83–72.68]). Pre-surgical ctDNA did not significantly predict recurrence (HR 0.99 [0.30–3.23]) or death (HR 3.23 [0.40–25.91]). In contrast, post-surgical ctDNA was associated with increased risk of recurrence (HR 3.32 [1.05–10.51]) and death (HR 5.97 [1.11–36.08]).</div></div><div><h3>Conclusion</h3><div>Post-surgical ctDNA detection was associated with poor outcomes in patients with endometrial cancer. These findings support the potential of ctDNA as a biomarker to personalize surveillance and guide post-surgical treatment strategies.</div></div>","PeriodicalId":11522,"journal":{"name":"Ejso","volume":"52 3","pages":"Article 111388"},"PeriodicalIF":2.9,"publicationDate":"2026-01-05","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145924282","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2026-01-05DOI: 10.1016/j.ejso.2026.111389
Ferdinando Carlo Maria Cananzi , Mattia Di Benedetto , Vittoria D'Amato , Laura Ruspi , Federico Sicoli , Salvatore Lorenzo Renne , Vittorio Lorenzo Quagliuolo , Laura Samà
{"title":"Inguinal “neoligament” reconstruction after groin soft tissue sarcoma resection: A novel surgical technique","authors":"Ferdinando Carlo Maria Cananzi , Mattia Di Benedetto , Vittoria D'Amato , Laura Ruspi , Federico Sicoli , Salvatore Lorenzo Renne , Vittorio Lorenzo Quagliuolo , Laura Samà","doi":"10.1016/j.ejso.2026.111389","DOIUrl":"10.1016/j.ejso.2026.111389","url":null,"abstract":"","PeriodicalId":11522,"journal":{"name":"Ejso","volume":"52 3","pages":"Article 111389"},"PeriodicalIF":2.9,"publicationDate":"2026-01-05","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145914927","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2026-01-05DOI: 10.1016/j.ejso.2026.111390
Anna Norbeck , Mihaela Asp , Susanne Malander , Päivi Kannisto
Background
Patients with advanced ovarian cancer (AOC) who undergo primary and interval debulking surgery are often anemic at diagnosis, with iron deficiency being the most common cause. The aim was to investigate whether preoperative anemia and iron deficiency impact short-term recovery.
Methods
This retrospective cohort study included 262 patients with AOC who underwent surgery at Skane University Hospital Lund, Sweden, between January 2020 and December 2023. Patients were divided into four groups, according to preoperative anemia and iron deficiency. Iron deficiency was defined as transferrin saturation (TSAT) < 0.20. Severe complications were defined as Clavien–Dindo (CD) grade ≥3. Logistic regression analyses were used to investigate the difference between patients with and without iron deficiency.
Results
Among patients with iron deficiency anemia, 24 % of patients had more than 1 cm of residual tumor at the end of surgery, compared to 6–8 % of patients with no anemia and/or no iron deficiency, (p 0.005). The rate of severe complications (CD ≥ 3) was higher for patients with iron deficiency, odds ratio 2.47 (95 % CI 1.11–5.50), than for patients with no iron deficiency, adjusted for the Aletti score, operating time and hemoglobin (Hb) level. There was no difference between groups regarding length of hospital stay.
Conclusion
Patients with iron deficiency anemia, were less likely to undergo radical or optimal surgery. Severe postoperative complications were more common in patients with iron deficiency, with or without anemia. These analyses indicate that iron deficiency is associated with more advanced disease and complex surgical procedures.
背景:晚期卵巢癌(AOC)患者在接受原发性和间断性减癌手术时,通常在诊断时贫血,缺铁是最常见的原因。目的是研究术前贫血和缺铁是否影响短期恢复。方法本回顾性队列研究纳入了2020年1月至2023年12月在瑞典隆德斯科纳大学医院接受手术的262例AOC患者。根据术前贫血和缺铁情况将患者分为四组。缺铁定义为转铁蛋白饱和(TSAT) & 0.20。严重并发症定义为Clavien-Dindo (CD)分级≥3级。采用Logistic回归分析探讨缺铁患者与非缺铁患者之间的差异。结果在缺铁性贫血患者中,24%的患者手术结束时肿瘤残留大于1cm,而无贫血和/或无缺铁患者的这一比例为6 - 8%,(p 0.005)。经Aletti评分、手术时间和血红蛋白(Hb)水平调整后,缺铁患者的严重并发症(CD≥3)发生率高于无缺铁患者,优势比为2.47 (95% CI 1.11-5.50)。在住院时间方面,两组之间没有差异。结论缺铁性贫血患者接受根治性或最佳手术治疗的可能性较小。严重的术后并发症在缺铁、伴或不伴贫血的患者中更为常见。这些分析表明,铁缺乏与更严重的疾病和复杂的外科手术有关。
{"title":"Iron deficiency restrains short-term recovery in patients undergoing surgery for advanced ovarian cancer","authors":"Anna Norbeck , Mihaela Asp , Susanne Malander , Päivi Kannisto","doi":"10.1016/j.ejso.2026.111390","DOIUrl":"10.1016/j.ejso.2026.111390","url":null,"abstract":"<div><h3>Background</h3><div>Patients with advanced ovarian cancer (AOC) who undergo primary and interval debulking surgery are often anemic at diagnosis, with iron deficiency being the most common cause. The aim was to investigate whether preoperative anemia and iron deficiency impact short-term recovery.</div></div><div><h3>Methods</h3><div>This retrospective cohort study included 262 patients with AOC who underwent surgery at Skane University Hospital Lund, Sweden, between January 2020 and December 2023. Patients were divided into four groups, according to preoperative anemia and iron deficiency. Iron deficiency was defined as transferrin saturation (TSAT) < 0.20. Severe complications were defined as Clavien–Dindo (CD) grade ≥3. Logistic regression analyses were used to investigate the difference between patients with and without iron deficiency.</div></div><div><h3>Results</h3><div>Among patients with iron deficiency anemia, 24 % of patients had more than 1 cm of residual tumor at the end of surgery, compared to 6–8 % of patients with no anemia and/or no iron deficiency, (<em>p 0.005</em>). The rate of severe complications (CD ≥ 3) was higher for patients with iron deficiency, odds ratio 2.47 (95 % CI 1.11–5.50), than for patients with no iron deficiency, adjusted for the Aletti score, operating time and hemoglobin (Hb) level. There was no difference between groups regarding length of hospital stay.</div></div><div><h3>Conclusion</h3><div>Patients with iron deficiency anemia, were less likely to undergo radical or optimal surgery. Severe postoperative complications were more common in patients with iron deficiency, with or without anemia. These analyses indicate that iron deficiency is associated with more advanced disease and complex surgical procedures.</div></div>","PeriodicalId":11522,"journal":{"name":"Ejso","volume":"52 3","pages":"Article 111390"},"PeriodicalIF":2.9,"publicationDate":"2026-01-05","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145915100","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2026-01-03DOI: 10.1016/j.ejso.2025.111378
S.T. Glazemakers , S.H.J. Ketelaers , H.B. Cornelisse , F. de Wit , I.T.A. Pereboom , G. van der Sluis , H. Smid-Nanninga , H.D. de Boer , I. Nielen , S.W. Polle , R. Bretveld , E.B. van Duyn , J. Tolenaar , J.W.A. Burger , J.G. Bloemen
Introduction
The value of continuing thromboprophylaxis after hospital discharge (extended prophylaxis) following colorectal cancer surgery is uncertain in modern surgical practices.
Methods
A multicentre, retrospective cohort study was conducted across 6 ERAS-adherent centres in the Netherlands, including 2409 patients who underwent elective colorectal cancer surgery between January 2018 and August 2023. Patients were categorized based on their hospital's thromboprophylaxis regimen: thromboprophylaxis until discharge or extended prophylaxis continued after discharge. The primary outcome was 90-day cumulative incidence of symptomatic VTE, with log-rank tests for group comparisons. Secondary outcomes included major bleeding complications (Clavien-Dindo grade ≥ III), and factors associated with occurence of postoperative VTE or major bleeding complications.
Results
The median duration of thromboprophylaxis was 4 (IQR 2–6) days in the until-discharge group (n = 1260) and 28 (IQR 18–28) days in the extended-prophylaxis group (n = 1149). The overall incidence of symptomatic VTE was 0.2 %, with no significant difference observed between the two groups (0.2 % vs. 0.2 %; p = 0.925). Major bleeding complications occurred more frequently in the extended-prophylaxis group (1.0 % vs. 2.0 %; p = 0.049). Multivariate analysis demonstrated that extended thromboprophylaxis was independently associated with major bleeding complications (OR2.002, 95 %CI 1.007–3.980), but not with VTE incidence.
Conclusion
The overall incidence of symptomatic VTE following elective colorectal cancer surgery within ERAS protocols was low. Thromboprophylaxis regimens continued after discharge were not associated with lower incidence of postoperative VTE, but were associated with a higher frequency of postoperative major bleeding complications. These findings suggest that routine extended thromboprophylaxis may be reconsidered in modern colorectal cancer surgery.
Clinical trial registration
registration number W22.176.
在现代外科实践中,结直肠癌手术后出院后继续血栓预防(延长预防)的价值尚不确定。方法在荷兰的6个eras附属中心进行了一项多中心、回顾性队列研究,包括2409名在2018年1月至2023年8月期间接受选择性结直肠癌手术的患者。根据医院的血栓预防方案对患者进行分类:在出院前进行血栓预防或在出院后继续进行延长预防。主要终点为90天症状性静脉血栓栓塞的累积发生率,采用对数秩检验进行组间比较。次要结局包括主要出血并发症(Clavien-Dindo分级≥III),以及与术后静脉血栓栓塞或主要出血并发症发生相关的因素。结果血栓预防的中位持续时间在出院组(n = 1260)为4 (IQR 2 ~ 6)天,在延长预防组(n = 1149)为28 (IQR 18 ~ 28)天。症状性静脉血栓栓塞的总发生率为0.2%,两组间差异无统计学意义(0.2% vs. 0.2%; p = 0.925)。大出血并发症在扩展预防组发生率更高(1.0% vs 2.0%; p = 0.049)。多因素分析表明,扩大血栓预防与大出血并发症独立相关(OR2.002, 95% CI 1.007-3.980),但与静脉血栓栓塞发生率无关。结论ERAS方案下择期结直肠癌手术后出现症状性静脉血栓栓塞的总体发生率较低。出院后继续进行血栓预防治疗与较低的术后静脉血栓栓塞发生率无关,但与较高的术后大出血并发症发生率相关。这些发现提示常规延长血栓预防在现代结直肠癌手术中可能被重新考虑。临床试验注册注册号W22.176。
{"title":"Extended thromboprophylaxis in enhanced recovery after surgery for colorectal cancer: a multicentre retrospective cohort study","authors":"S.T. Glazemakers , S.H.J. Ketelaers , H.B. Cornelisse , F. de Wit , I.T.A. Pereboom , G. van der Sluis , H. Smid-Nanninga , H.D. de Boer , I. Nielen , S.W. Polle , R. Bretveld , E.B. van Duyn , J. Tolenaar , J.W.A. Burger , J.G. Bloemen","doi":"10.1016/j.ejso.2025.111378","DOIUrl":"10.1016/j.ejso.2025.111378","url":null,"abstract":"<div><h3>Introduction</h3><div>The value of continuing thromboprophylaxis after hospital discharge (extended prophylaxis) following colorectal cancer surgery is uncertain in modern surgical practices.</div></div><div><h3>Methods</h3><div>A multicentre, retrospective cohort study was conducted across 6 ERAS-adherent centres in the Netherlands, including 2409 patients who underwent elective colorectal cancer surgery between January 2018 and August 2023. Patients were categorized based on their hospital's thromboprophylaxis regimen: thromboprophylaxis until discharge or extended prophylaxis continued after discharge. The primary outcome was 90-day cumulative incidence of symptomatic VTE, with log-rank tests for group comparisons. Secondary outcomes included major bleeding complications (Clavien-Dindo grade ≥ III), and factors associated with occurence of postoperative VTE or major bleeding complications.</div></div><div><h3>Results</h3><div>The median duration of thromboprophylaxis was 4 (IQR 2–6) days in the until-discharge group (n = 1260) and 28 (IQR 18–28) days in the extended-prophylaxis group (n = 1149). The overall incidence of symptomatic VTE was 0.2 %, with no significant difference observed between the two groups (0.2 % vs. 0.2 %; p = 0.925). Major bleeding complications occurred more frequently in the extended-prophylaxis group (1.0 % vs. 2.0 %; p = 0.049). Multivariate analysis demonstrated that extended thromboprophylaxis was independently associated with major bleeding complications (OR2.002, 95 %CI 1.007–3.980), but not with VTE incidence.</div></div><div><h3>Conclusion</h3><div>The overall incidence of symptomatic VTE following elective colorectal cancer surgery within ERAS protocols was low. Thromboprophylaxis regimens continued after discharge were not associated with lower incidence of postoperative VTE, but were associated with a higher frequency of postoperative major bleeding complications. These findings suggest that routine extended thromboprophylaxis may be reconsidered in modern colorectal cancer surgery.</div></div><div><h3>Clinical trial registration</h3><div>registration number W22.176.</div></div>","PeriodicalId":11522,"journal":{"name":"Ejso","volume":"52 3","pages":"Article 111378"},"PeriodicalIF":2.9,"publicationDate":"2026-01-03","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145914929","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2026-01-02DOI: 10.1016/j.ejso.2026.111384
Xin Li , Yi-Fei Liu , Chen-Yao Zhou , Jun Lu , Guo-Wei Wang , Zi-Jie Tang , Zi-Chao Tu , Yong-Yi Zeng , Wei Guo , Ji-Li Li , Jia-Hao Xu , Chao Li , Ming-Da Wang , Feng Shen , Fei Wu , Tian Yang , Eastern HepatoBiliary Alliance (EHBA) group
Background
Current tumour-node-metastasis (TNM) staging for hepatocellular carcinoma (HCC) relies primarily on anatomical factors without incorporating tumour biological characteristics, limiting prognostic precision. This study aimed to develop and validate a novel staging system integrating serum biomarkers alpha-fetoprotein (AFP) and protein induced by vitamin K absence or antagonist-II (PIVKA-II) with conventional TNM classification to enhance prognostic stratification following hepatectomy.
Methods
This multicentre cohort study included patients undergoing curative hepatectomy for HCC at six hospitals in China. The APTNM staging system was constructed by combining preoperative AFP (≥200 μg/L = 1 point), PIVKA-II (≥400 mAU/mL = 1 point), and AJCC 8th edition TNM stage (stages I–III = 1–3 points). Patients were classified as APTNM stage I (1 point), stage II (2–3 points), or stage III (4–5 points). Prognostic performance was evaluated using Kaplan-Meier analysis, multivariate Cox-regression, net reclassification improvement (NRI), and time-dependent receiver operating characteristic (ROC) curves.
Results
Among 660 HCC patients, the APTNM staging system demonstrated clear stratification for 5-year overall survival (OS) [stage I (n = 195), 47.7 %; stage II (n = 316), 28.1 %; stage III (n = 149), 15.3 %; P < 0.001] and recurrence-free survival (RFS) (stage I, 29.4 %; stage II, 12.7 %; stage III, 0.0 %; P < 0.001). Multivariate analysis confirmed APTNM staging as an independent predictor of both OS (stage II: HR 1.592, 95 % CI 1.209–2.096; stage III: HR 2.314, 1.668–3.211; both P < 0.001) and RFS (stage II: 1.556, 1.230–1.969; stage III: 2.159, 1.623–2.872; both P < 0.001). Time-dependent NRI values ranged from 0.20 to 0.26 for OS and 0.18–0.31 for RFS across 5-year follow-up, demonstrating substantial improvement over conventional TNM staging. Time-dependent ROC analysis consistently showed superior performance for the APTNM staging.
Conclusions
The APTNM staging system successfully integrates tumour biomarkers with anatomical factors, providing significantly enhanced prognostic stratification compared with conventional TNM staging. This biologically informed approach may facilitate more precise risk stratification and guide individualised postoperative surveillance and adjuvant therapy decisions for patients with HCC.
{"title":"Development and validation of the APTNM staging system: Integration of serum biomarkers with TNM classification for enhanced prognostic stratification following hepatectomy for hepatocellular carcinoma","authors":"Xin Li , Yi-Fei Liu , Chen-Yao Zhou , Jun Lu , Guo-Wei Wang , Zi-Jie Tang , Zi-Chao Tu , Yong-Yi Zeng , Wei Guo , Ji-Li Li , Jia-Hao Xu , Chao Li , Ming-Da Wang , Feng Shen , Fei Wu , Tian Yang , Eastern HepatoBiliary Alliance (EHBA) group","doi":"10.1016/j.ejso.2026.111384","DOIUrl":"10.1016/j.ejso.2026.111384","url":null,"abstract":"<div><h3>Background</h3><div>Current tumour-node-metastasis (TNM) staging for hepatocellular carcinoma (HCC) relies primarily on anatomical factors without incorporating tumour biological characteristics, limiting prognostic precision. This study aimed to develop and validate a novel staging system integrating serum biomarkers alpha-fetoprotein (AFP) and protein induced by vitamin K absence or antagonist-II (PIVKA-II) with conventional TNM classification to enhance prognostic stratification following hepatectomy.</div></div><div><h3>Methods</h3><div>This multicentre cohort study included patients undergoing curative hepatectomy for HCC at six hospitals in China. The APTNM staging system was constructed by combining preoperative AFP (≥200 μg/L = 1 point), PIVKA-II (≥400 mAU/mL = 1 point), and AJCC 8th edition TNM stage (stages I–III = 1–3 points). Patients were classified as APTNM stage I (1 point), stage II (2–3 points), or stage III (4–5 points). Prognostic performance was evaluated using Kaplan-Meier analysis, multivariate Cox-regression, net reclassification improvement (NRI), and time-dependent receiver operating characteristic (ROC) curves.</div></div><div><h3>Results</h3><div>Among 660 HCC patients, the APTNM staging system demonstrated clear stratification for 5-year overall survival (OS) [stage I (n = 195), 47.7 %; stage II (n = 316), 28.1 %; stage III (n = 149), 15.3 %; <em>P</em> < 0.001] and recurrence-free survival (RFS) (stage I, 29.4 %; stage II, 12.7 %; stage III, 0.0 %; <em>P</em> < 0.001). Multivariate analysis confirmed APTNM staging as an independent predictor of both OS (stage II: HR 1.592, 95 % CI 1.209–2.096; stage III: HR 2.314, 1.668–3.211; both <em>P</em> < 0.001) and RFS (stage II: 1.556, 1.230–1.969; stage III: 2.159, 1.623–2.872; both <em>P</em> < 0.001). Time-dependent NRI values ranged from 0.20 to 0.26 for OS and 0.18–0.31 for RFS across 5-year follow-up, demonstrating substantial improvement over conventional TNM staging. Time-dependent ROC analysis consistently showed superior performance for the APTNM staging.</div></div><div><h3>Conclusions</h3><div>The APTNM staging system successfully integrates tumour biomarkers with anatomical factors, providing significantly enhanced prognostic stratification compared with conventional TNM staging. This biologically informed approach may facilitate more precise risk stratification and guide individualised postoperative surveillance and adjuvant therapy decisions for patients with HCC.</div></div>","PeriodicalId":11522,"journal":{"name":"Ejso","volume":"52 2","pages":"Article 111384"},"PeriodicalIF":2.9,"publicationDate":"2026-01-02","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145920794","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2026-01-02DOI: 10.1016/j.ejso.2026.111383
Thea Piso , Michael Gerken , Stefan Rolf Benz , Monika Klinkhammer-Schalke , Alois Fürst , Melanie C. Langheinrich , Saskia Thies , Stefan Loth , Constanze Schneider , Fabian Reinwald , Jacqueline Müller-Nordhorn , Andrea Sackmann , Sylke Ruth Zeissig , Bianca Franke , Vinzenz Völkel , Moritz Schmelzle , Ulf Kulik
Introduction
Resection plays a pivotal role in the treatment of rectal cancer. The aim of this study is to compare the long-term outcomes of laparoscopic, open surgical and robotic approaches.
Material and methods
The study cohort contains data of 24,725 patients with rectal cancer and curative surgery between 2010 and 2022 from a pooled database of cancer registries of ten German federal states. Primary outcome was overall survival (OS). Secondary outcomes were cumulative loco-regional recurrence (CLR) and recurrence free survival (RFS) calculated via univariable and multivariable analyses, and matched-pair analyses.
Results
Of the 24,725 patients, 12,561 (50.8 %) were treated with open, 11,248 (45.5 %) with laparoscopic and 916 patients (3.7 %) with robotic-assisted resections. In multivariable Cox regression analysis, OS was higher in the minimal invasive surgery groups compared to the open surgery group with a HR of 0.775 (p < 0.001) for the laparoscopic and HR of 0.768 (p = 0.006) for the robotic group. A comparison of robotic to open surgery regarding RFS showed a significant difference in favor of robotic surgery in multivariable Cox regression (HR 0.834, p = 0.046). The rate of CLR was lower in the robotic compared to the laparoscopic surgery group. Additionally, we found a lower conversion rate in the robotic group as compared to the laparoscopic group.
Conclusion
These findings from real-life data confirm current recommendations for minimal invasive rectal resection. There was a trend towards better outcomes after robotic compared to laparoscopic surgery. However, further studies are needed to investigate this issue and to provide definitive evidence.
{"title":"Elective surgery in rectal cancer: long term results of a German network comparison of open, laparoscopic, and robotic surgery","authors":"Thea Piso , Michael Gerken , Stefan Rolf Benz , Monika Klinkhammer-Schalke , Alois Fürst , Melanie C. Langheinrich , Saskia Thies , Stefan Loth , Constanze Schneider , Fabian Reinwald , Jacqueline Müller-Nordhorn , Andrea Sackmann , Sylke Ruth Zeissig , Bianca Franke , Vinzenz Völkel , Moritz Schmelzle , Ulf Kulik","doi":"10.1016/j.ejso.2026.111383","DOIUrl":"10.1016/j.ejso.2026.111383","url":null,"abstract":"<div><h3>Introduction</h3><div>Resection plays a pivotal role in the treatment of rectal cancer. The aim of this study is to compare the long-term outcomes of laparoscopic, open surgical and robotic approaches.</div></div><div><h3>Material and methods</h3><div>The study cohort contains data of 24,725 patients with rectal cancer and curative surgery between 2010 and 2022 from a pooled database of cancer registries of ten German federal states. Primary outcome was overall survival (OS). Secondary outcomes were cumulative loco-regional recurrence (CLR) and recurrence free survival (RFS) calculated via univariable and multivariable analyses, and matched-pair analyses.</div></div><div><h3>Results</h3><div>Of the 24,725 patients, 12,561 (50.8 %) were treated with open, 11,248 (45.5 %) with laparoscopic and 916 patients (3.7 %) with robotic-assisted resections. In multivariable Cox regression analysis, OS was higher in the minimal invasive surgery groups compared to the open surgery group with a HR of 0.775 (p < 0.001) for the laparoscopic and HR of 0.768 (p = 0.006) for the robotic group. A comparison of robotic to open surgery regarding RFS showed a significant difference in favor of robotic surgery in multivariable Cox regression (HR 0.834, p = 0.046). The rate of CLR was lower in the robotic compared to the laparoscopic surgery group. Additionally, we found a lower conversion rate in the robotic group as compared to the laparoscopic group.</div></div><div><h3>Conclusion</h3><div>These findings from real-life data confirm current recommendations for minimal invasive rectal resection. There was a trend towards better outcomes after robotic compared to laparoscopic surgery. However, further studies are needed to investigate this issue and to provide definitive evidence.</div></div>","PeriodicalId":11522,"journal":{"name":"Ejso","volume":"52 3","pages":"Article 111383"},"PeriodicalIF":2.9,"publicationDate":"2026-01-02","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145915356","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2026-01-01DOI: 10.1016/j.ejso.2025.111220
Robert Mansel
{"title":"The European Quality Assurance scheme for Breast Cancer Services","authors":"Robert Mansel","doi":"10.1016/j.ejso.2025.111220","DOIUrl":"10.1016/j.ejso.2025.111220","url":null,"abstract":"","PeriodicalId":11522,"journal":{"name":"Ejso","volume":"52 ","pages":"Article 111220"},"PeriodicalIF":2.9,"publicationDate":"2026-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145914906","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}